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Abstract
Background: Patients with cancer often suffer from fatigue and decreased quality of life which might be related to the
breakdown of essential amino acid tryptophan.
Methods: In 50 patients with lung cancer we examined fatigue and the deterioration of quality of life in patients using the
Functional Assessment of Cancer Therapy Anemia (FACT-An) and -Fatigue (FACT-F) subscales of FACT-General and the
Mental adjustment to Cancer (MAC) questionnaires. Results were compared with tryptophan breakdown as well as serum
concentrations of immune activation markers.
Results: Scores of psychological tests correlated significantly with tryptophan breakdown and with circulatory markers of
inflammation. However, immune activation and tryptophan breakdown were not related to MAC scores.
Conclusions: Tryptophan breakdown relates with fatigue and impaired quality of life in patients with lung cancer, while
declining tryptophan levels are not associated with patients’coping strategies.
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Introduction
Patientswithmalignantdisease often suffer from sustained fatigue
and a reduced quality of life (QoL) [1–3]. Apart from cancer-related
cachexia and tumor-related anemia, additional factors such as anti-
tumor chemotherapy contribute to the development of neuropsy-
chiatric complications and deterioration of quality of life (QoL) [4].
Neuropsychiatric symptoms comprise subtle cognitive changes,
sleep disturbances, anxiety, but also depression, which strongly
affects patients’ QoL. Depression is encountered in about 10–25%
of cancer patients, a rate that is much higher than in the general
population [5–7], but similar in chronically ill patients with other
medical diagnoses [8]. The prevalence of fatigue in cancer patients
is even higher [9], e.g. a study in patients with lung cancer reported
about a prevalence offatigue of 78% [10]. Infact, fatigue isthe most
commonly reported symptom in cancer patients and greatly affects
their QoL [9]. The feeling of tiredness and lack of energy appear to
resultfrom amultifactorialetiology,both physicalandpsychological
components play a role [11,12]. Anemia is considered to be a main
factor causing fatigue [13,14], but also other factors like dyspnoea,
non-refreshing sleep and depression can contribute [15–17]. In
addition, immune activation has been proposed to induce fatigue
and depression in patients with cancer or other chronic diseases
[17–22].
The development of behavioral symptoms has been attributed
to increased concentrations of pro-inflammatory cytokines [21–
23]. Thereby an increased catabolism of the essential amino acid
L-tryptophan, which is a precursor of the neurotransmitter
serotonin, has been suggested to play a major role in this setting
[24–26]. The enzyme indoleamine 2,3-dioxygenase (IDO) con-
verts tryptophan to kynurenine preferentially upon stimulation
with pro-inflammatory cytokines like interferon-c (IFN-c) [18,27–
29]. In parallel, IFN-c induces the enzyme GTP-cyclohydrolase I
in human macrophages to form and release neopterin [27,30].
Enhanced activation of IDO in parallel with increased
neopterin formation has been described in patients with hemato-
logical malignancies [31], colorectal cancer [32,33], gynecological
malignancies [34] and also in other malignant diseases [35].
Interestingly, enhanced tryptophan breakdown was found to be
related to an impaired QoL in patients suffering from colorectal
cancer [33], and it was also predictive for an increased fatigue
feeling and worse QoL in a population of patients with different
types of cancer [35]. As these studies suggest that immune-
mediated tryptophan breakdown might play a role in the
development of fatigue and might also be involved in the
impairment of QoL in patients suffering from lung cancer, we
wanted to better characterize the relationship between concen-
trations of immune activation markers and QoL and fatigue by
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36956using well-established and validated questionnaires and also self-
assessment scores of patients. Furthermore, we also investigated
whether coping strategies and physical performance of patients are
related to tryptophan breakdown and immune activation.
Methods
Participants
Fifty patients suffering from lung cancer were recruited from the
district hospital of Natters near Innsbruck/the Tyrol. Patients’
characteristics as well as their concomitant medication and
presence/absence of infection are shown in Table 1.
Within the scope of routine blood examinations, fractions of
serum samples of patients were collected and frozen at 220uC
until analysis. To assess patients’ performance status, the ECOG
scala (Eastern Cooperative Oncology Group) was used.
The study was approved by the ethical committee of the
Innsbruck Medical University and patients gave written informed
consent to participate in the study. All clinical investigation has
been conducted according to the principles expressed in the
Declaration of Helsinki.
Psychometric Tests
FACT-anemia and FACT-fatigue subscale, MAC. To
assess fatigue of patients, the fatigue subscale of FACT-G
(FACT-F) and the Anemia subscale of FACT-G questionnaire
(FACT-An), respectively, were employed [36]. The FACT-F is a
13-item fatigue subscale utilizing a five-point Likert self-report
scale ranging from 0 (not at all) to 4 (very much). After accounting
for reverse-scored items, answers are summed across the subscales
and added for a total score, with higher scores indicative of less
fatigue feeling. The total score varies from 0 (worst condition) to 52
(best condition). The FACT-An subscale is a questionnaire
assessing fatigue and anemia-related concerns in patients with
cancer and comprises questions of the 13-item fatigue subscale and
seven questions specifically investigating non–fatigue-based ane-
mia symptoms. Scores range from 0 to 80, with higher scores
representing better functioning and well-being of patients.
Patients also completed MAC questionnaires (Mental adjustment
to Cancer) to assess their coping strategies [37]. This 40-items
questionnaire includes five subscales focusing on responses to being
diagnosed with cancer. Items are rated on a scale ranging from
‘‘definitely does not apply to me’’ (1) to ‘‘definitely applies to me’’
(4). The fighting spirit (FS) subscale assesses whether the patient
viewscancerasa challenge and takesanactiveandoptimisticrole in
his or her treatment; the helplessness-hopelessness (H) subscale
assesses whether the patient has an attitude of uncontrollability and
hopelessness toward cancer and its outcome; the anxious preoccu-
pation (AP) subscale assesses whether the patient has an overly
anxious and diffuse preoccupation with cancer; and the fatalism-
stoic acceptance (F) subscale assesses whether the patient exhibits a
passive, fatalistic, and stoic acceptance of cancer. To assess the
general attitude of patients towards their disease (rather positive or
negative adjustment), overall scores were calculated: the Summary
Positive Adjustment (SPA) Scale and the Summary Negative
Adjustment (SNA) Scale [38].
Self-assessment of patients. In addition to the FACT-
scores we also asked patients to assess their fatigue feeling on a
scale from 1–5 (patients’ self-report: 1=no fatigue; 5=high grade
of fatigue), independently of a questionnaire. Patients furthermore
scored their QoL on the same scale from 1–5 (patients’ self-report:
1=best score, very good; 5=worst score, very bad). The purpose
of this self-assessment was to compare the patients’ view with
results of the FACT-questionnaires.
Measurements
Serum concentrations of tryptophan and kynurenine were
measured by high performance liquid chromatography as
described [39]. After precipitation of protein with trichloroacetic
acid, tryptophan was measured by fluorescence detection at
Table 1. Baseline characteristics of patients.
50 subjects (37 men, 13 women), median age 65 years
Type of lung cancer: Non small lung cell cancer (NSCLC; n=38), Small lung cell cancer (SLCC, n=12) 38 (%)
Tumor stage of patients: UICC Stage I (n=4), stage II (n=8), stage III (n=16), stage IV (n=22)
Smokers and former smokers (n) 40 (80%)
Patients with infection (n) 9 (18%)
Patients who survived the following 3 months (n) 40
Concomitant medication of patients:
Chemotherapy (n) 36
Radiotherapy (n) 8
Antidepressant medication (n) 21
Morphin treatment (n) 5
Anti-obstructive treatment (n) 31
Proton pump inhibitor (n) 37
Analgesic therapy (n) 26
Anti-infective therapy (n) 9
Antihypertensive medication (n) 21
Cardiovascular medication (n) 26
Thyroid medication (n) 8
Uricosurics 9
doi:10.1371/journal.pone.0036956.t001
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was monitored by UV-absorption at 360 nm wavelength. L-
nitrotyrosine was used as an internal standard, and standard
preparations containing tryptophan, kynurenine and nitrotyrosine
in the presence of albumin underwent the whole procedure like
serum specimens. To estimate IDO activity, the ratio of the
concentrations of the enzyme product kynurenine to the substrate
tryptophan (kynurenine to tryptophan ratio=Kyn/Trp) was
calculated [40].
Neopterin concentrations were determined by ELISA
(BRAHMS Diagnostica, Hennigsdorf, Germany), and C-reactive
protein (CRP) concentrations were determined with Ektachem
Clinical Chemistry Slides according to instructions of the
manufacturers. Blood sedimentation rate was measured according
to Westergren.
Statistical Analyses
As not all data sets showed normal distribution, non-parametric
tests were employed (Kruskal-Wallis, Mann-Whitney U-test, two-
sided tests). Spearman rank correlation analysis was applied to
assess associations between variables, partial correlation analysis
was employed to adjust for confounders like tumor progression,
age, gender or treatment status. To account for multiple testing
Bonferroni correction was applied, i.e. only p-values ,0.01 were
regarded as significant. Univariate binary logistic regression
analysis (inclusion method) was used to identify parameters
indicative for survival and fatigue. Multivariate linear regression
analysis was performed to further investigate predictors of
psychological outcomes (FACT-F/FACT-An and MAC). Vari-
ables included in forward predictor selection were clinical and
sociodemographic variables as well as blood parameters. P–values
,0.05 were considered to indicate statistical significance.
To assess the internal consistency of the used questionnaires and
subscales, Cronbach’s alpha coefficients were calculated.
Results
Psychological Outcomes
Patients with lung cancer had a mean FACT-An score of
51.262.3 (mean 6 S.E.M.) and a mean FACT-F score of
31.361.9. According to the FACT-F subscale, seven patients
suffered from very severe (scores 0–14) and 7 more patients from
severe fatigue (scores 15–24). Eleven patients complained about
moderate fatigue (scores 25–34), while 14 patients reported about
little (FACT-F scores 35–44) and 11 about no fatigue (FACT-F
scores .45). The internal consistency of the used fatigue
questionnaires was very good (Cronbach’s alpha for FACT-F
subscale was .9247, Cronbach’s alpha for FACT-An subscale was
.9214).
When patients scored their fatigue on a self-assessment scale
from 1–5 (1=no fatigue; 5=high grade of fatigue), a mean score
of 2.6 (6.1) was achieved. One patient reported about very severe
fatigue, 4 patients about severe fatigue and 22 patients about
moderate fatigue. One patient did not feel fatigued at all, while 21
reported about little fatigue.
Patients’ self-assessment of their QoL (with 1=best score, very
good; 5=worst score, very bad) showed a mean score of 2.7 (6.1).
One patient assessed his QoL as very good, while 9 patients
reported about a bad QoL; 21 patients assessed their QoL as
satisfying, while 19 patients expressed that their QoL was
moderately impaired.
Performance status of patients according to ECOG criteria was
3.0 in the mean (6.1), 16 patients had an ECOG performance
status of 2, i.e. they were ambulatory and able to care for
themselves, but not able to work anymore, while 17 were only
capable of limited self-care (EGOG score 3), and 17 were
completely disabled (ECOG score 4) and thus had to be cared
for by others.
Mean MAC scores for ‘‘Fighting spirit’’ were 48.961.0
(maximum score: 64), 22.16.6 for ‘‘Anxious preoccupation’’
(maximum score: 36), 11.96.6 for ‘‘Hopelessness’’ (maximum
score: 24), 1.56.2 for ‘‘Avoidance’’ (maximum score: 4) and the
mean score for Fatalism was 2.86.5 (maximum score: 32).
According to these scores patients had a strong fighting spirit,
but also tended to be fatalistic and anxious. To assess the general
attitude of patients towards their disease (rather positive or
negative adjustment), also overall scores were calculated: the
Summary Positive Adjustment (SPA) Scale was 52.261.1 and the
Summary Negative Adjustment (SNA) Scale was 35.661.2. The
internal consistency of SPA and SNA scales was higher than that
of the original five subscales (Cronbach’s alpha for SPA was .8002
and .8126 for SNA Scale), Cronbach’s alpha coefficients varied
from .3747 (MAC-Fatalism) to .7819 (MAC-Hopelessness).
Patients who died from cancer within 3 months had lower
FACT- F (mean 6 SEM 2364 vs. 3362, p,0.01) and FACT-An
scores (mean 6 SEM 3965, vs. 5163; p,0.01) than survivors,
while self-assessment scores regarding fatigue and QoL and MAC
scores did not differ.
Patients under treatment with antidepressants (n=21) had
lower FACT-An and FACT-F scores than patients without
antidepressant medication (both p,0.05), but higher MAC-FS
and MAC-H scores (both p,0.05). No differences regarding
psychological scores were seen between patients with NSCLC and
SCLC, as well as between patients with higher or lower tumor
stage.
Relationship between Different Psychological Tests
To assess the psychological situation of patients with lung
cancer, overall scores for FACT-An, FACT-F and MAC were
calculated. These scores as well as the patients’ self-assessment
scores for fatigue and QoL were correlated with each other.
Significant correlations were seen between fatigue scores
(FACT-F, FACT-An) and patients’ self-assessment of fatigue
feeling and their QoL. Spearman rank coefficients for fatigue self-
assessment and FACT-F and FACT-An were rs=20.547 for
FACT-F and rs=20.537 for FACT-An (both p,0.001). Also
patients’ assessment of their QoL was strongly related to FACT-
scores: Spearman rank coefficients for QoL and FACT-F and
FACT-An were rs=20.466 for FACT-F and rs=20.494 for
FACT-An, respectively (all p,0.001). Patients who reported
stronger fatigue mostly also claimed to experience a reduced
QoL (rs=0.663, p,0.001).
Patients with higher MAC- scores for ‘‘Fighting spirit’’ reported
about less fatigue (rs=0.489 for FACT-F and rs=0.521 for
FACT-An; both p,0.001), whereas higher MAC-scores for
‘‘Hopelessness’’ coincided with more fatigue (rs=20.419 for
FACT-F and rs=20.424 for FACT-An; all p,0.01). Positive
adjustment to cancer scores were associated with higher FACT-F
and FACT-An scores (i.e., less fatigue feeling; rs=0.441 for
FACT-F and rs=0.570 for FACT-An; both p,0.001), while
negative adjustment to cancer was correlated with a stronger
fatigue feeling (rs=20.429 for FACT-F and rs=20.420 for
FACT-An; both p,0.01).
Tryptophan Metabolism, Immune Activation, Anemia
and Tumor Stage
The mean tryptophan concentration in patients was
53.462.3 mmol/L (mean 6 S.E.M.), mean kynurenine concen-
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52.366.0 mmol/mmol. In comparison to the ranges observed in
healthy controls (35), the cancer patients presented with lower
tryptophan and higher kynurenine levels, and accordingly with
increased Kyn/Trp. Higher tryptophan levels and lower Kyn/Trp
were observed in patients who survived the following 3 months of
observation (both p,0.01, see also Fig. 1).
Patients with SCLC showed similar tryptophan and kynurenine
concentrations as patients with NSCLC, but were significantly
younger (p,0.05). No differences regarding tryptophan metabo-
lism were seen between patients with advanced tumor stages
(UICC-stage 3 or 4) and those with earlier tumor stages.
Concentrations of inflammatory and immune activation mark-
ers were also increased in comparison to reference ranges
(neopterin: 12.361.4 nmol/L, CRP: 4.076.98 mg/dl).
Patients who died within 3 months had higher CRP levels than
survivors (p,0.01), while neopterin concentrations did not differ
significantly. Interestingly, neither neopterin nor CRP concentra-
tions were associated with tumor stage in our population.
Mean hemoglobin concentrations in patients was
13.260.3 mg/dl, 18 patients (15 men, 3 women) suffered from
anemia with hemoglobin concentrations ,12 mg/dl for women
and ,13 mg/dl for men). Hemoglobin levels were lower in
patients with higher tumor stage (rs=2.393, p,0.01), and the
majority of the anemic patients (n=11, 61.1%) had a more
progressed tumor disease (UICC-stage III or IV). Patients who
died within the next 3 months of observation had lower
hemoglobin levels than patients who survived (p,0.01). Lower
hemoglobin levels were also predictive for death within the next 3
months of observation. Patients with anemia (n=18) presented
with higher inflammation and immune activation markers (CRP:
7.361.9 vs. 1.36.4 mg/dl, p,0.001; neopterin: 16.663.2 nmol/
L vs. 9.061.0 nmol/L, p,0.05) and lower tryptophan levels
(42.963.0 mmol/L vs. 59.062.9 mmol/L), and accordingly with
an increased Kyn/Trp (65.6611.6 vs. 45.867.3 mmol/mmol) as
compared to cancer patients without anemia
Enhanced tryptophan degradation coincided with immune
activation: Significant associations were seen between inflamma-
tory markers and tryptophan catabolism: Patients with high
neopterin concentrations had higher kynurenine levels (rs=0.410,
p,0.01), a higher Kyn/Trp (rs=0.556, p,0.001) and higher
CRP concentrations (rs=0.558, p,0.001). CRP levels correlated
with tryptophan concentrations rs=20.468, p=0.001) and Kyn/
Figure 1. FACT-F (upper left) and FACT-AN scores (upper right) as well as concentrations of C-reactive protein (CRP; lower left) and
kynurenine to tryptophan ratios (Kyn/Trp; lower right) of patients with lung cancer who have died (n=10) or were still alive or after
3 months of follow-up (all group comparisons between alive and dead p,0.01).
doi:10.1371/journal.pone.0036956.g001
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was related to inflammation.
Inflammation and tryptophan degradation were both associated
with decreased hemoglobin values: Significant associations existed
between hemoglobin concentrations and CRP (rs=20.563,
p,0.001), Kyn/Trp (rs=20.416, p,0.01) as well as tryptophan
levels (rs=0.533, p,0.001).
Relationship between Psychological Scores and
Tryptophan Breakdown
Patients with moderate to severe fatigue according to FACT-F
scores (score 0–34, n=25) presented with higher concentrations of
inflammation markers, a higher degree of tryptophan breakdown
and lower hemoglobin levels than patients with little or no fatigue
according to their FACT-F scores (score .34; n=25; see Table 2).
Furthermore, they reported about a worse QoL (p,0.05) and had
worse ECOG scores (p,0.001, Table 2).
Significant associations existed between FACT-An, FACT-F
scores and markers of immune activation and tryptophan
catabolism as detailed in Table 3 and shown in Figures 2 and 3.
Interestingly, significant correlations were only found in patients
without antidepressant treatment, while associations between
fatigue scores and immune activation and tryptophan breakdown
did not exist in patients under antidepressant treatment.
Also performance status of patients and self-assessment of their
QoL were correlated with tryptophan concentrations (see also
Table 2. Mean concentrations (6 SEM) of investigated lab parameters and psychological scores of lung cancer patients with
moderate to severe and little or no fatigue, respectively (n.s.=not significant).
Patients with moderate to severe fatigue (n=25)
Patients with little or no fatigue
(n=25) p-value
Hemoglobin (mg/dl) 12.560.4 13.860.4 p,0.05
CRP (mg/dl) 6.2561.74 2.3360.99 p,0.05
Neopterin (nM) 14.562.1 10.061.6 p,0.05
Tryptophan (mM) 49.662.9 57.263.4 n.s.
Kynurenine (mM) 2.660.2 2.260.2 n.s.
Kyn/Trp (mM/mM) 60.769.1 43.967.5 p,0.05
Leukocytes (/ml) 10.161.3 8.860.9 p,0.05
Quality of life 3.060.2 2.560.1 p,0.05
Fatigue 3.060.2 2.360.1 p,0.001
Fighting spirit 45.961.27 51.861.23 p,0.01
Anxious preoccupation 22.960.90 21.360.85 n.s.
Fatalism 21.260.66 20.460.77 n.s.
Hopelessness 13.460.91 10.360.56 p,0.05
Avoidance 1.6860.18 2.260.24 n.s.
ECOG score 3.460.1 2.560.1 p,0.001
doi:10.1371/journal.pone.0036956.t002
Table 3. Spearman rank correlations (two-sided) between investigated parameters of immune activation, haemoglobin levels and
fatigue scores as well as patients’ self-assessment scores and ECOG scores.
FACT-F score FACT-An score Quality of life Fatigue ECOG score
Neopterin (nM) 20.412 * 20.412 * 0.181 0.178 0.378 *
p=0.003 p=0.003 n.s. n.s. p=0.007
Tryptophan (mM) 0.376 * 0.409 * 20.382 * 20.347 20.277
p=0.007 p=0.003 p=0.006 p=0.01 p=0.05
Kynurenine (mM) 20.123 20.112 20.104 0.113 20.238
n.s. n.s. n.s. n.s. p=0.09
Kyn/Trp (mM/mM) 20.323 20.329 0.146 0.232 0.376 *
p=0.02 p=0.02 n.s. n.s. p=0.007
CRP (mg/dl) 20.459 * 20.468 * 0.219 0.226 0.310
p=0.002 p=0.001 n.s. n.s. p=0.04
Hemoglobin (mg/dl) 0.400 * 0.426 * 20.312 20.223 20.339
p=0.005 p=0.003 p=0.03 n.s. p=0.02
Only p-values #0.01 were regarded as significant (after Bonferroni correction for multiple testing). Significant correlations are indicated by asterisks.
doi:10.1371/journal.pone.0036956.t003
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scores (rs=0.400 for FACT-F, rs=0.426 for FACT-An, both
p,0.01, Table 3 and Fig. 2).
Hemoglobin and CRP levels were predictive for the presence of
moderate to severe fatigue in binary logistic regression analysis
(hemoglobin: OR 0.716 [0.513–0.998]; CRP: OR 1.177 [1.033–
1.341], both p,0.05).
None of the MAC-scores correlated with laboratory markers of
immune activation, tryptophan breakdown or hemoglobin levels.
ECOG scores were higher in patients with lower fighting spirit
(rs=20.519, p,0.001) and with higher hopelessness scores
(rs=0.378, p,0.01) as well as in patients with lower scores of
positive adjustment to cancer (rs=20.544, p,0.001).
Multivariate regression analysis was performed to further
investigate predictors of psychological outcomes (FACT-F/An
and MAC). Variables included in forward predictor selection were
clinical and sociodemographic variables as well as blood param-
eters. In addition to bivariate associations shown in the correlation
analyses above, we found multivariate predictor sets for FACT-F
(CRP and antidepressant intake; explained variance 26.3%;
p=0.001) and MAC-Fatalism (sex, age, tumor stage; explained
variance 28.9%; p,0.001).
Discussion
A high percentage of the patients with bronchus carcinoma
(50%) suffered from moderate to severe fatigue according to
FACT-F scores. Patients with fatigue acclaimed a significantly
worse QoL and performed worse than those with little or no
fatigue, which is well in line with earlier studies [1–3]. The self-
assessment of patients regarding their fatigue showed a good
correlation with results of the FACT-F and FACT-An scores
indicating that results of self-assessment scores (which are gained
by a simple question) are similar to and even comparable to results
Figure 2. Correlations of FACT-AN and FACT-F- scores with tryptophan and hemoglobin concentrations: tryptophan vs. FACT-AN
(upper left): rs=0.409, p,0.01; tryptophan vs. FACT-F (upper right): rs=0.376, p,0.01; hemoglobin vs. FACT-AN (lower left):
rs=0.426, p,0.01; hemoglobin vs. FACT-F (lower right): rs=0.400, p,0.01.
doi:10.1371/journal.pone.0036956.g002
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can characterize patients’ fatigue feeling more explicitly.
Patients who suffered from a higher degree of fatigue presented
with lower tryptophan concentrations and a higher degree of
immune activation. Higher Kyn/Trp and lower tryptophan
concentrations in parallel with higher concentrations of inflam-
mation markers were also observed in patients who performed
worse according to their ECOG score and in patients with
anemia.
Anemia is supposed to be one of the important triggers of
fatigue, and immune activation and inflammation are well
established to play a major role in the development of anemia of
chronic disease (ACD) [14,41]. Studies in patients with cancer
and also HIV infection have demonstrated correlations between
neopterin and hemoglobin levels [31,35,41–43]. Enhanced
t r y p t o p h a nb r e a k d o w ni np a r a l l e lw i t hh i g h e rn e o p t e r i nl e v e l s
has been observed in patients with ACD [44], indicating that
enhanced tryptophan catabolism and as a consequence,
tryptophan depletion, might affect hematopoiesis. Significant
correlations between hemoglobin and tryptophan concentra-
tions on the one hand, and elevated Kyn/Trp on the other hand
in our patients would be well in line with this hypothesis.
Figure 3. Tryptophan concentrations are related with fatigue feeling in patients according to their FACT-F score (upper left),
patients’ self-assessment of their fatigue (upper right), patients’ physical performance (ECOG score; lower left), and patients’ self-
assessment of their quality of life (lower right).
doi:10.1371/journal.pone.0036956.g003
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b r e a k d o w nt h a np a t i e n t sw i t hn o r m a lh e m o g l o b i nc o n c e n t r a -
tions. More than one third of our patients (36%) were anemic,
and anemia was a significant predictor of fatigue. However as
already shown previously [45], anemia is prominently involved,
but certainly not the only factor in the pathogenesis of cancer-
related fatigue. Fatigue and also reduced physical performance
are among other symptoms frequently encountered in patients
with depression [46].
Interestingly, associations between immune-mediated trypto-
phan breakdown and fatigue were only significant in patients
without antidepressant medication, which fits well with results of
an earlier study in HIV-infected patients [47]. In that study,
correlations between immune activation and Becks depression
score as well as QoL Score MQoL-HIV were encountered only in
patients without antidepressant treatment. Our data thus indirect-
ly indicate that immune activation and tryptophan breakdown
might be related with the development of fatigue. Antidepressant
treatment appeared to influence the relationship between fatigue
feeling and the biochemical pathways we investigated in our
population of lung cancer patients: Patients under antidepressant
treatment had lower tryptophan and higher CRP levels than those
without this medication, also indicating indirectly that enhanced
tryptophan breakdown might be involved in the development of
depression. However, this finding may be biased by the fact that
we had only 50 patients and a high percentage of patients with
antidepressant medication.
Tryptophan is the precursor of neurotransmitter serotonin, and
thus, increased tryptophan breakdown might lead to decreased
serotonin formation or trigger depressive-like behaviour by the
accumulation of neurotoxic metabolites of kynurenine: Elevated
concentrations of neurotoxins quinolinic acid and 3-hydroxy-
kynurenine have been shown in the CSF and also brains of
patients with inflammatory neurological diseases [48]. Quinolinic
acid interferes with the NMDA receptor and alleviates NMDA-
mediated induction of apoptosis of primary neuronal cell cultures,
while 3-hydroxy-kynurenine generates free radicals, which can
cause oxidative stress and lipid peroxidation [49]. Kynurenic acid
on the other hand is an endogenous neuroprotect [50], the
formation of which is increased in patients with inflammatory
neurological diseases [48], but in fact, the balance between
neurotoxic and neuroprotective kynurenine metabolites seems to
be shifted towards neurotoxins in patients with chronic immune
activation [51,52] and also in patients with major psychiatric
disorders [53].
Also a recent study in mice points to a crucial role of IDO in the
development of depressive-like behaviour: Chronic infection with
BCG induced depressive-like behaviour in normal mice, while
IDO-deficient mice were resistant to BCG-induced depressive-like
behaviour [54]. Interestingly, IDO-deficient mice showed a
normal induction of pro-inflammatory cytokines in response to
BCG infection, supporting the concept of a central role of IDO
and tryptophan in the development of depression. However, there
is also the possibility that tryptophan catabolism can be stress-
induced when hepatic tryptophan 2,3-dioxygenase (TDO) is
upregulated. In fact, IDO expression in cells or tissues was not
examined in our cancer patients, but the significant relationship
found between neopterin and Kyn/Trp supports a role of IDO in
the cytokine-induced tryptophan metabolic changes observed in
our patients.
Recent data by Capuron and coworkers are in line with this
hypothesis, in fact increased tryptophan catabolism was associ-
ated with the depressive symptoms of lassitude, reduced
motivation, anorexia, and pessimism, while disturbed phenylal-
anine/tyrosine/dopamine metabolism was shown to be related
with neurovegetative symptoms, like sleep disturbance, digestive
symptoms, sickness, motor symptoms and fatigue in elderly
persons [55].
As one would expect patients with fatigue had higher
hopelessness scores and less fighting spirit, and their positive
adjustment to cancer was worse. MAC scores were not correlated
with immune activation or tryptophan catabolism, and were also
not predictive for the survival of patients. Patients’ attitude towards
their disease might influence both, their fatigue feeling and also
their immune activation status, however, from our data we cannot
draw conclusions regarding this relationship- in fact, it could also
be the other way round.
Patients with higher fatalism score were those with more
progressed tumor stage, physical performance according to their
ECOG score was better in patients with higher fighting spirit and
with low hopelessness scores. It would be interesting to know
whether inflammation-induced noradrenergic disturbances [56]
are associated to this spectrum of symptoms. Also the question,
whether psychological intervention might be effective to interfere
with immune-mediated tryptophan degradation, appears to be
worth further examination- as psychological intervention was
shown to alleviate depressive symptoms [57].
There are several limitations of this study: The cohort studied
is quite heterogeneous with different types of lung cancer,
different stages and different treatment regimes including
antidepressants and chemotherapy. However, the analysis of
the various subgroups would be underpowered because of the still
small size of the study population. As highlighted in the
introduction section, sleep disturbances might relate to the
development of fatigue and depression in patients [15–17], but
no validated sleep quality questionnaire such as the Pittsburgh
Sleep Quality Index has been performed. Thus, the relationship
between the metabolic changes found could not be analyzed. Also
no direct measure of the enzyme pathways of tryptophan
metabolism has been performed to further support the potential
roles of IDO vs. and TDO. Finally this cross-sectional study can
only provide correlational evidence but cannot prove any cause-
effect relationship.
In conclusion, this study confirms that fatigue is frequently
encountered in patients with lung cancer and indicates that
tryptophan breakdown might play a role in the development of
fatigue and probably also depression in these patients. Still, it has
to be kept in mind that our population of lung cancer patients was
quite small, and that results are therefore rather preliminary.
Further longitudinal studies with more patients with cancer are
therefore needed to enable a better understanding of underlying
biochemical processes. They may also be able to provide new
information, as to whether therapeutic modulation of tryptophan
availability may affect fatigue and depression in patients with
cancer.
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